JOHNS HOPKINS UNIVERSITY

The Gates Foundation has awarded $13.5 million across multiple projects to reduce monoclonal antibody manufacturing costs from the current $50-100 per gram to just $10 per gram, making these life-saving treatments accessible in low-resource settings.

Intensity Therapeutics published phase 1/2 clinical results for INT230-6 in eBioMedicine, showing a 75% disease control rate and 11.9-month median overall survival in heavily pretreated patients with advanced metastatic cancers.

Virtuoso Surgical's robotic system received FDA Breakthrough Device Designation for bladder lesion removal via en bloc excision, positioning the company at the forefront of innovative bladder cancer care.

A randomized, double-blinded trial of 99 patients across 21 medical centers demonstrated that shunt surgery significantly improves walking speed and reduces falls in older adults with idiopathic normal pressure hydrocephalus.

Analysis of FDA adverse event data reveals dual orexin receptor antagonists (DORAs) have only 2.6% abuse-related adverse events, significantly lower than benzodiazepines (27.7%) and Z-drugs (15.3%).

Rapafusyn Pharmaceuticals closed an over-subscribed $44 million Series A financing round, adding BioTrack Capital and Yonjin Capital as new investors alongside existing backers.

Raina Biosciences announced publication of its GEMORNA platform data in Science, marking the world's first generative AI platform purpose-built for mRNA design and optimization.

Precision BioSciences' PBGENE-HBV demonstrated substantial antiviral activity in all three patients in the lowest dose cohort, achieving 47-69% reductions in hepatitis B surface antigen levels.

A BMJ investigation has revealed evidence of serious misreporting in two clinical trials that were pivotal to ticagrelor's approval by the FDA and UK regulators.

Infinity Bio closed an $8 million Series A financing round led by Illumina Ventures to expand its proprietary MIPSA™ antibody reactome profiling platform.